Challenges and Opportunities in Drug Development

Post 1
The development of drugs is faced with the double challenge of the increased pressure on
pricing and increased costs. To avoid the lack of perceived commercial perspective which will
leave unmet medical needs. To cub this the pharmaceutical companies and other
stakeholders are strategizing how to improve the drug Research and Development efficacy.
The areas to be focused on are; adaptive designs, public–private partnerships, and big data.
Public–private partnerships have different forms with regard to duration, scope, number of
participants and type. They can be strategic alliances, project-specific collaborations or large
multi-party consortia. Each of these forms offers opportunities unique from the other and they
are faced with challenges that are distinct. In the collaborations, studies that are investigator-
initiated are becoming increasingly popular although they have ethical, legal and financial
constraints. The adaptive trial designs are also increasingly discussed. However, adaptive
designs are not to be used as euphemism to repurpose trials that have failed; rather before
trial starts specifications and careful planning is required. The Big Data offers an opportunity
to use the existing information into knowledge that is used in drug development and
discovery. A key challenge in Big Data is respecting privacy, and attaining voluntary informed
consent.
From all the above it can be concluded that development of new drugs is no longer a job for
pharmaceutical industry only. Rather it should be multidisciplinary; pharmaceutical
companies, regulatory authorities, academic investigators, payers, bodies for health
technology assessment. Of most important, patients will increasingly shape ways of
developing new drugs for the medical needs.
Reason to be one of the best posts:
The increasing costs in the development of drugs and the increased pressure on the drug
pricing challenges the pharmaceutical industry current models. These models; adaptive
designs, public-private partnerships, and the use of big data offers opportunities to improve
the efficacy of developing drugs. Only the time will prove which approaches been most
beneficial. At present time, all models are promising in increasing the efficiency in drug
development and research more efficient. Although to implement this the limitations of this
models should be understood.
Post 2
Personalized medicine and tailored therapeutic has led to the development patient-centred
medicine. Improving the patients’ health outcomes, considering patients’ preferences, their
values, their objectives and the availability of the economic resources are its major objectives.
The patient-centred medicine requires a paradigm shift between doctors and patients’
relationship. It also requires the patient-oriented research, that is not based on the evaluating
the of medical interventions in the average patient, but coming up with best solutions for
individual patients, that is individualization of care. In addition to this, the growth and
development of the information that is based on technologies is of help in filling the gap
between the clinical practice and the clinical research.
Reason to be one of the best posts:
The industry's key role is to develop medicines and science for primary(prevention) and
curative/treatment of diseases. In the dynamics of the current environment in health care.
The industry efforts are on initiatives to improve and impact patients and carers. The most
valuable data set in trails is the patients-reported outcomes. Their reports are able to capture
information that is relevant to the patients, identifies their preferences, and come up with